ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 16619045

Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway.

Chapman EJ and 5 others. Oncogene, 2006. Cited by 80 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Papers, record 16619045. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16619045

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway.
PubMed
Journal
Oncogene
PubMed
Year
2006
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
80
iCite
Relative citation ratio, by iCite
1.71
iCite
Revised in PubMed
2026-10-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chapman EJE J
2Hurst CDC D
3Pitt EE
4Chambers PP
5Aveyard JSJ S
6Knowles MAM A

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell Transformation, NeoplasticMajor topic
DNA-Binding ProteinsMajor topic
Genes, RetinoblastomaMajor topic
Genes, p16Major topic
TelomeraseMajor topic
UrotheliumMajor topic
Base Sequence
Cells, Cultured
DNA Primers
Humans

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114,871,870dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data.Bioinformatics2004https://conductscience.org/library/papers/14871870PubMed
212,717,449Telomerase modulates expression of growth-controlling genes and enhances cell proliferation.Nat Cell Biol2003https://conductscience.org/library/papers/12717449PubMed
310,534,765Dominant genetic alterations in immortalization: role for 20q gain.Genes Chromosomes Cancer1999https://conductscience.org/library/papers/10534765PubMed
41,908,564Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter.Nature1991https://conductscience.org/library/papers/1908564PubMed
515,608,686hTERT antagonizes p53-induced apoptosis independently of telomerase activity.Oncogene2005https://conductscience.org/library/papers/15608686PubMed
615,507,675Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.J Mol Diagn2004https://conductscience.org/library/papers/15507675PubMed
710,599,415Replicative senescence in human uroepithelial cells.Adv Exp Med Biol1999https://conductscience.org/library/papers/10599415PubMed
89,774,969p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.Mol Cell1998https://conductscience.org/library/papers/9774969PubMed
912,573,439Tumor suppression by Ink4a-Arf: progress and puzzles.Curr Opin Genet Dev2003https://conductscience.org/library/papers/12573439PubMed
108,943,005Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.Proc Natl Acad Sci U S A1996https://conductscience.org/library/papers/8943005PubMed

1 to 10 of 46

See all 46 references

Cited by61

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.

PMIDTitleJournalYearIn PapersSource
39,611,476Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation.Mol Med Rep2025https://conductscience.org/library/papers/39611476PubMed
38,676,926Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.Cell Rep2024https://conductscience.org/library/papers/38676926PubMed
36,713,366TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance.Front Immunol2022https://conductscience.org/library/papers/36713366PubMed
36,180,582The urothelium: a multi-faceted barrier against a harsh environment.Mucosal Immunol2022https://conductscience.org/library/papers/36180582PubMed
34,588,866The effect of antibiotics and photodynamic therapy on extended-spectrum beta-lactamase (ESBL) positive of Escherichia coli and Klebsiella pneumoniae in urothelial cells.Saudi J Biol Sci2021https://conductscience.org/library/papers/34588866PubMed
34,181,805The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets.Cancer Sci2021https://conductscience.org/library/papers/34181805PubMed
33,396,213MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients.Diagnostics (Basel)2020https://conductscience.org/library/papers/33396213PubMed
31,108,958Phosphoproteomic Profiling Identifies Aberrant Activation of Integrin Signaling in Aggressive Non-Type Bladder Carcinoma.J Clin Med2019https://conductscience.org/library/papers/31108958PubMed
30,952,872ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.Sci Rep2019https://conductscience.org/library/papers/30952872PubMed
30,627,420A prospect of cell immortalization combined with matrix microenvironmental optimization strategy for tissue engineering and regeneration.Cell Biosci2019https://conductscience.org/library/papers/30627420PubMed

1 to 10 of 61

See all 61 cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CDKN2A1,029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene
RB15,925PubTator's text mininghttps://conductscience.org/library/genes/5925NCBI Gene
TERT7,015PubTator's text mininghttps://conductscience.org/library/genes/7015NCBI Gene
TP537,157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16619045

GET https://conductscience.org/api/papers/v1/16619045/references?page=2

API referenceFor AI assistants